The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC
is its intimate association with the gut microbiota, which forms an essential part of the tumour …

Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …

Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer
immunotherapy. In a B cell lymphoma patient cohort from five centers in Germany and the …

Microorganisms within the gut and other niches may contribute to carcinogenesis, as well as
sha** cancer immunosurveillance and response to immunotherapy. Our understanding of …

The gut microbiota have long been recognized to play a key role in human health and
disease. Currently, several lines of evidence from preclinical to clinical research have …

Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …

Human microorganisms, including bacteria, fungi, and viruses, play key roles in several
physiological and pathological processes. Some studies discovered that tumour tissues …

Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also
predispose patients to immune-related adverse events like immune-mediated colitis (IMC) …